CPX-351, developed by Jazz Pharmaceuticals, is positioned to potentially offer a more effective and tolerable treatment option for adult patients with first relapse AML compared to standard intensive salvage therapies. Given the high unmet need in this patient population, successful outcomes could lead to significant market capture in the oncology sector, particularly in the AML treatment landscape. Competitive analysis indicates that while there are existing therapies, CPX-351's unique formulation may provide a differentiated profile. Diligence should focus on post-trial commercialization strategies, pricing, and reimbursement pathways, as well as potential partnerships for distribution.